miragenews.com/compound-pro...
But now, UC Davis Health researchers have developed a new compound that could offer alternatives for patients with treatment-resistant tumors. The molecule is called LX-1. It simultaneously targets androgen receptor (AR) variants and the enzyme AKR1C3, which are both known to drive resistance.
“Prostate tumors can develop multiple resistance mechanisms that allow them to live without external androgen, negating efforts to treat them,” said Director of Urologic Research Allen Gao, who is also the Ralph de Vere White Professor. “Once resistance develops, patients have few therapeutic choices, and their survival rate is quite poor.”
Normally, androgen receptors need androgen to be activated. But these AR variants are active all the time, driving tumor growth even without androgen stimulation.
Prostate tumors have other tricks to evade treatment. In the face of androgen deprivation, they can even make their own androgen, creating a closed circuit that defies intervention. Tumors often hijack AKR1C3 to make androgens.
Erleada in the EU for metastatic prostate cancer
My search result for: can ivermectin lower psa levels 
Question about availability of Lu-177 therapy
Updates to de novo metastatic prostate cancer treatment 
